29results about "Silicon compound active ingredients" patented technology

The application belongs to the field of medicinal chemistry, and provides a compound as an Akt kinase inhibitor, and particularly relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation method of the compound, a pharmaceutical composition containing the compound, and use of the compound in preparation of a medicament for treating an Akt kinase related disease.

A transient oil-in-simethicone emulsion for oral administration wherein 5 simethicone is present from 50% to 80% by weight of the emulsion. Also described is the process for the preparation of the transient oil-in-simethicone emulsion and capsule dosage form.

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

Pharmaceutical composition comprising a Pickering oil-in-water emulsion containing an aqueous phase, a vegetable oil phase, and an organomodified phyllosilicate, particularly for its use in increasing TAFA4 production, and possibly for increasing serotonin production, for its use as a cutaneous anti-inflammatory agent and / or wound-healing agent and / or as a cutaneous anti-allergy agent. Figure to be published with the abstract: none.

The application provides a pH and near-infrared light dual-response photocage compound and application thereof. The photocage compound comprises a silicon-xanthene ion skeleton and a molecular residue Cargo, and the silicon-xanthene ion skeleton is connected with the Cargo through a Linker. The PPG core skeleton of the application not only responds to near-infrared light irradiation, but also introduces a response mechanism to pH conditions. Compared with the existing PPG which only depends on light triggering, the dual-gating of 'environment (tumor acidity) + external triggering (NIR light)' is realized, the spatiotemporal accuracy and targeting selectivity of active molecule release are significantly improved, and the non-specific release in non-target tissues is reduced, thereby reducing systemic toxicity.

The purpose of the present invention is to provide a novel B0AT1 inhibitor.　The present invention pertains to a compound, or a salt thereof, having an inhibitory action on B0AT1, the compound being represented by formula (I) [the symbols in the formula are as defined in the description]. The present invention also pertains to: a B0AT1 inhibitor containing the compound; and a pharmaceutical composition containing the compound. One embodiment of the present invention is a medical drug that is suitable for preventing and / or treating, for example, amino acid metabolism disorders such as phenylketonuria, urea cycle disorders, hypertyrosinemia (type 1-3), hypermethioninemia, maple syrup urine disease, homocystinuria, nonketotic hyperglycinemia, propionic acidemia, methylmalonic acidemias, and isovaleric acidemia.

The present invention relates to heterocyclic compounds, pharmaceutical compositions thereof, and methods which may be useful as inhibitors of IGF-1R for the treatment or prevention of thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy (TAO), or Graves' ophthalmopathy or orbitopathy (GO).

The present invention relates to nitrogen-containing heterocyclic compounds, processes for their preparation and their use. The nitrogen-containing heterocyclic compounds have the structure of general formula I, wherein the substituents are defined as described in the specification and claims. The nitrogen-containing heterocyclic compounds of the present invention are useful as therapeutic agents for the treatment of inflammatory diseases, ischemic diseases, degenerative diseases, tumor-related conditions and diseases.

The present disclosure provides a method of treating cystic fibrosis or a CFTR-mediated disease comprising administering Compound (I), a deuterated derivative thereof, or a pharma- ceutically acceptable salt of any of the foregoing, e.g., administering about 1 mg to about 400 mg of Compound (I). The present disclosure also provides pharmaceutical compositions comprising Compound (I), a deuterated derivative thereof, or a pharma- ceutically acceptable salt of any of the foregoing, and optionally one or more additional CFTR-modulating agents. The present invention relates to modulators of the cystic fibrosis transmembrane conductance regulator (CFTR), pharmaceutical compositions containing the modulators, methods of treating cystic fibrosis and CFTR-mediated disorders using such modulators and pharmaceutical compositions, and processes for making such modulators.

Provided herein are compounds of Formula (I), a compound selected from any of the compounds in Table 1, Table 2, Table 3, or a pharmaceutically acceptable salt or deuterated form thereof, wherein R1, R2, R3 and R4 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of formula (I), or a compound selected from any of the compounds in Table 1, Table 2, Table 3, or pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of formula (I) or pharmaceutically acceptable salt or deuterated form thereof, e.g., in treating 5-HT2A receptor associated diseases or disorders.

The present invention provides a pyrazole compound represented by a formula (1) or a salt thereof, and a novel fungicide, in particular, agricultural-horticultural fungicide that contains it as an active ingredient. The formula indicates a structure in which G represents G-1, G1 represents C1-C6 haloalkyl, etc., T represents an oxygen atom, etc., RX represents C1-C6 alkyl, etc., RY represents a hydrogen atom, etc., R1 represents a hydrogen atom, etc., R2 represents a hydrogen atom, etc., R3 represents a hydrogen atom, etc., Ra represents a hydrogen atom, etc., Z represents Z-1, etc., Z1 represents C1-C6 alkyl, etc., m5 and n5 each represent an integer of 0, 1, 2, 3, 4, or 5, and p represents an integer of 0 or 1.

The present invention provides compounds, compositions, and methods for use in treating, controlling, or preventing parasitic invasion or infection in animals. [Solution] The variable element is a compound of the following formula, or a salt thereof, a composition containing these compounds, and a method for treating, controlling, or preventing parasitic invasion or infection in animals by administering an effective amount of these compounds to an animal in need. JPEG2026090328000305.jpg5683

Methods for treatment of brittle, broken, cracked or otherwise damaged nail plates. The inventive methods involve application of the formulated composition to the nail utilizing a treatment composition of an aqueous-organic medium containing a Michael addition monoadduct or bisadduct of a complex of a diamine and maleic anhydride, allowing the monoadduct and / or the bisadduct to penetrate the surface of the nail plate into the internal region of the plate.

The present invention relates generally to methods of use and compositions useful for increasing procollagen-1 expression in the skin, increasing lysyl oxidase expression in the skin, inhibiting melanogenesis in the skin, and / or increasing expression of elastin in the skin. The composition includes a combination of one or more of Himanthalia elongata extract, Undaria pinnatifida extract, Saussurea involucrata extract, Morus alba fruit extract, Citrus aurantium dulcis (orange) callus culture extract, Argania spinosa kernel extract, and / or Opuntia tuna fruit extract.

The present invention relates to a quinazoline compound for inducing decomposition of G12D mutant KRAS protein. The present invention provides a quinazoline compound represented by the following formula (I) or a salt thereof, and also provides a pharmaceutical composition comprising the quinazoline compound or the salt thereof and one or more pharmaceutically acceptable excipients. The quinazoline compound has excellent effects of inducing decomposition of G12D mutant KRAS protein and G12D mutant KRAS inhibitory activity, and can be used as a therapeutic agent for pancreatic cancer, thereby accomplishing the present invention. The quinazoline compound or the salt thereof or the pharmaceutical composition can be used as a therapeutic agent for pancreatic cancer.

The present disclosure relates to tricyclic tetrahydroisoquinoline derivatives, processes for their preparation and their use in medicine. In particular, the present disclosure relates to tricyclic tetrahydroisoquinoline derivatives of general formula (I), processes for their preparation and pharmaceutical compositions containing them, as well as their use as estrogen receptor modulators and their use in the manufacture of a medicament for the treatment of a disease or disorder mediated or dependent on the estrogen receptor. Wherein the substituents of general formula (I) are as defined in the description.

This specification describes isoindolinone compounds and pharmaceutical compositions comprising such compounds. Furthermore, it describes methods for treating neurological disorders such as Huntington's disease (HD).

The monoclonal antibody specifically binds to CD25, and the conjugate of anti-CD25 antibody are described.The CD25-specific monoclonal antibody and its conjugate do not block the binding of IL-2 to CD25, and induce little or no antibody-dependent cell-mediated cytotoxicity (ADCC).The anti-CD25 antibody and conjugate can be used, for example, to target photoimmunotherapy to T regulatory (Treg) cells in tumor beds to enhance local host immune response against tumors.

This invention belongs to the field of medicinal chemistry, specifically relating to a small molecule donor for the light-controlled release of nitric oxide and carbon monoxide and its uses. The small molecule donor is a compound of formula I, wherein X and R... 1‑8 As defined in the text, the maximum absorption wavelength of the fluorescent compound obtained after photoactivation is in the range of 541-640 nm, and the maximum emission wavelength is in the range of 565-655 nm. The small molecule donors of nitric oxide and carbon monoxide of the present invention can release nitric oxide and carbon monoxide after light irradiation, which can be used to treat wounds caused by multidrug-resistant bacteria. At the same time, the fluorescent compound converted after the release of nitric oxide and carbon monoxide can be used to track the release location of nitric oxide and carbon monoxide in real time.

The invention relates to silicon phthalocyanine compounds containing pyridine groups with anti-cancer (cancer-therapeutic) and antioxidant effects, which exhibit activity in cancer cells that show resistance to metal-containing compounds, have a broader activity spectrum compared to metal-containing compounds, possess lower toxicity and reduced side effects compared to metal-containing compounds, and can be used as potential anti-tumor drugs, as well as to the methods of synthesis of these compounds.

This invention relates to compositions and methods for invasive and non-invasive procedural skincare. In particular, it relates to topical compositions for promoting skin repair, anhydrous topical compositions, methods for preparing a skin bed prior to dermatological treatment, and methods for promoting skin repair after dermatological treatment. More generally, this invention relates to skin care treatments, and more specifically to compositions and methods for promoting skin health, skin regeneration, skin repair, skin bed preparation, and enhanced wound healing.

The present invention provides compounds having functional substituents in a specific spatial arrangement, devices containing said functional substituents, methods for producing the same, and uses thereof. The present invention relates to a compound represented by the following general formula (5). JPEG2022008530000121.jpg46170 X is CR 1 A and A' are the same or different and are aromatic ring structures having 6 ring atoms; ETG is an organic electron transport group (ETG) from the group of electron-deficient heterocyclic aromatic groups, ETG being selected from triazinyl groups, pyrimidyl groups, pyrazinyl groups, etc.; Z is a single bond or a divalent group; W is NR 1 , O or S, and R 4 are identical or different for each occurrence and in each case have one or more R 2 an aromatic ring having 6 to 60 aromatic ring atoms which may be substituted by a group, and R 1 , R 2 is H etc.

The application belongs to the technical field of antioxidant biomaterials, and particularly relates to a pentacyclic alkene free radical compound and a rhamnolipid free radical composite material and application. In view of the problems of poor stability and limited biological application of existing free radical antioxidant materials, the application provides a pentacyclic alkene free radical compound and a synthesis method, which is controllably synthesized through three-step reaction, and the yield and product stability are improved by optimizing the reaction conditions. The application also provides a rhamnolipid free radical composite material, which is coated with the pentacyclic alkene free radical compound by using rhamnolipid. The composite material has good antioxidant activity, can effectively reduce the ROS level in the epidermal keratinocytes caused by UVB in vitro application, and can achieve the effect of preventing photoaging, and is expected to be applied to the preparation of antioxidant, anti-aging drugs, food, health products, and washing and care products, and has high stability and strong antioxidant capacity, and can achieve the anti-aging effect of antioxidant and cell repair double-effect gain.

A kind of nitrogen-containing heterocyclic protein inhibitor compound, its stereoisomer, tautomer or pharmaceutically acceptable salt, also provides preparation of nitrogen-containing heterocyclic compound and its use, the drug prepared using the compound is widely used in the treatment of diseases, wherein the diseases include multiple types of autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, lupus erythematosus, neurodermatitis, dermatitis, psoriasis, psoriatic arthritis, Crohn's disease, Sjogren's syndrome and scleroderma.

The present invention relates to a new oily composition based on liquid alkanes for preventing and / or treating pediculosis, in particular pediculosis of the head in humans or on animal fur.

The present invention relates to a pharmaceutical composition comprising aluminum phosphate gel, magnesium hydroxide, simethicone, DL-carnitine hydrochloride, and chlorhexidine salt. The pharmaceutical composition of the present invention can be effectively used as a pharmaceutical composition by having excellent preservative capacity.